Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Hemic and Lymphatic Diseases | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Herbal medicine | 1 |
Biosimilar | 1 |
Colony-stimulating factors | 1 |
Top 5 Target | Count |
---|---|
DAT(Dopamine transporter) | 1 |
EPO receptor(Erythropoietin receptor) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. Netherlands |
First Approval Date22 Dec 2022 |
Target |
Mechanism Dopamine reuptake inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date05 Dec 1955 |
Target |
Mechanism EPO receptor agonists |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. European Union [+3] |
First Approval Date27 Aug 2007 |
Start Date21 Jun 2024 |
Sponsor / Collaborator |
Start Date12 Jan 2021 |
Sponsor / Collaborator |
Start Date12 Jan 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Epoetin alfa(Sandoz International GmbH) ( EPO receptor ) | chronic renal failure anemia More | Approved |
Echinacea purpurea/Eleutherococcus senticosus (root dry extract) | Common Cold More | Approved |
Methylphenidate Hydrochloride ( DAT ) | Attention Deficit Disorder With Hyperactivity More | Pending |
Nicotinamide ( PARP1 ) | Hyperphosphatemia More | Pending |